Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Vogt-Koyanagi-Harada disease


Other Names for this Disease
  • Uveomenigitic syndrome
  • VKH disease
  • VKH syndrome
  • Vogt-Koyanagi-Harada syndrome
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might Vogt-Koyanagi-Harada disease be treated?

Management of Vogt-Koyanagi-Harada (VKH) disease should involve various specialists including dermatologists, ophthalmologists, and neurologists.[1] Experts agree that successful therapy for VKH disease involves early and aggressive treatment with systemic corticosteroids.[2][3][1] For people who don't respond to this treatment or who cannot withstand side effects, immunomodulatory therapy (which alters the body's immune response) should be started.[2] While there is increasing evidence supporting the use of immunomodulatory therapy in almost all affected people, there is ongoing research to determine exactly when this treatment should be started and who should receive it.[2][4] Surgery for glaucoma is necessary in some people.[2] Other treatments for VKH disease are symptomatic and supportive.[3]

You can view more detailed information about the treatment of VKH disease on Medscape's Web site.
Last updated: 1/13/2015

References
  1. Olivier Calvetti, Caroline Laurent-Coriat, Michel Paques. VOGT-KOYANAGI-HARADA DISEASE. Orphanet. March, 2009; Accessed 1/12/2015.
  2. R Christopher Walton. Vogt-Koyanagi-Harada Disease. Medscape Reference. February 12, 2014; http://reference.medscape.com/article/1229432-overview. Accessed 1/13/2015.
  3. VOGT-KOYANAGI-HARADA DISEASE. NORD. February 12, 2014; http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/968/viewAbstract. Accessed 1/12/2015.
  4. Urzua CA et. al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. January 7, 2015; [Epub ahead of print]:


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Vogt-Koyanagi-Harada disease. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • Orphanet is a European reference portal for information on rare diseases and orphan drugs.  Access to this database is free of charge.
Other Names for this Disease
  • Uveomenigitic syndrome
  • VKH disease
  • VKH syndrome
  • Vogt-Koyanagi-Harada syndrome
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.